Current Problems in Cancer
Volume 34, Issue 2 , Pages 131-149 , March 2010

Current Problems with Systemic Treatment of Advanced Hepatocellular Cancer

References 

  1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576
  2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–1491
  3. http://www.cancer.org/docroot/stt/stt_0.asp
  4. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234(1):63–70
  5. Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatoly. 1998;28(5):1241–1246
  6. More E, Kaspa RT, Sheiner P, et al. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med. 1998;129(8):643–653
  7. Kew M. Hepatic tumors and cysts. In:  Feldman M,  Sleisenger M,  Scharschmidt B,  Klein S editor. ed 6. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathology/Diagnosis/Management. vol 1:Philadelphia, PA: WB Saunders; 1998;p. 1364–1387
  8. Godley P, Sandler RS. Digestive diseases in the United States: epidemiology and impact. 1994;NIH publication no. 94-1447
  9. Llovet J, Ricci S, Mazzaferro V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol. 2007;25(Suppl):18S
  10. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674–687
  11. Feo F, Frau M, Tomasi ML, et al. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med Maywood. 2009;234(7):726–736
  12. Thorgeirsson SS. Hunting for tumor suppressor genes in liver cancer. J Hepatol. 2003;37(4):739–741
  13. Bruix J, Boix L, Sala M, et al. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5(3):215–219
  14. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27(1):55–76
  15. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009;286(1):52–59
  16. Koike K. Pathogenesis of HCV-associated HCC: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol Res. 2007;37(Suppl 2):S115–S120
  17. Chung YH, Kim JA, Song BC, et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer. 2000;89(5):977–982
  18. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med. 2003;3(6):573–588
  19. Wiesenauer CA, Yip-Schneider MT, Wang Y, et al. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg. 2004;198(3):410–421
  20. Osada S, Kanematsu M, Imai H, et al. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg. 2005;201(3):405–411
  21. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatoly. 2005;41(2):307–314
  22. Alexia C, Fallot G, Lasfer M, et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol. 2004;68(6):1003–1015
  23. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4(4):677–685
  24. Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver. 1999;19(4):318–325
  25. Okano J, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver. 1999;19(2):151–159
  26. Yamaguchi R, Yano H, Iemura A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatoly. 1998;28(1):68–77
  27. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/STAT pathways in human HCC. Gastroenterology. 2006;130(4):1117–1128
  28. Bekaii-Saab T, Markowitz J, Prescott N, et al. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009;15(18):5895–5901
  29. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 2006;25(27):3778–3786
  30. Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52(5):706–712
  31. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008;48(1):83–90
  32. Giambartolomei S, Covone F, Levrero M, et al. Sustained activation of the Raf/MEK/erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene. 2001;20(20):2606–2610
  33. Ahmad T, Eisen T. Kinase inhibition with bay 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10(18 Pt 2):6388S–6392S
  34. Wilhelm SM, Carter C, Tang L, et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the ref/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109
  35. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008;68(16):6779–6788
  36. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34
  37. Abou-Alfa GK, Knox J, et al. Final results of phase II, randomized, double-blind study of sorafenib plus doxorubicin and placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer. 2007;5(4):Abstract 3500
  38. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657–6663
  39. O'Dwyer PJ, Giantonio BJ, Levy DE, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperatvie Oncology Group's study E1203. J Clin Oncol. 2006;24:4143
  40. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(3):581–589
  41. Gruenwald V, Wilkens L, Gebel M, et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol. 2007;25:Abstract 4598
  42. O'Neil BH, Williams-Goff LW, Kauh J, et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol. 2009;27(Suppl):Abstract e15574
  43. Louafi S, Hebbar M, Rosmorduc O, et al. Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): results of the phase II study ERGO. J Clin Oncol. 2007;25(18S):Abstract 4594
  44. O'Neil BH, Bernard SA, Goldberg RM, et al. Phase II study of oxliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol. 2008;26(suppl):Abstract 4604
  45. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110(5):1059–1067
  46. Govindarajan R, Seigel E, Makhoul I, et al. Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC). J Clin Oncol. 2009;27(suppl):Abstract e15557
  47. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002;21(31):4863–4871
  48. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell. 2001;105(3):391–402
  49. Cha MY, Kim CM, Park YM, et al. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatoly. 2004;39(6):1683–1693
  50. Ding Q, Xia W, Liu JC, et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell. 2005;19(2):159–170
  51. Fukutomi T, Zhou Y, Kawai S, et al. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatoly. 2005;41(5):1096–1105
  52. Park JY, Park WS, Nam SW, et al. Mutations of beta-catenin and axing I genes are a late event in human hepatocellular carcinogenesis. Liver Int. 2005;25(1):70–76
  53. Nomoto S, Kinoshita T, Kato K, et al. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer. 2007;97(9):1260–1265
  54. Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006;12(18):5369–5376
  55. Piao Z, Park C, Park JH, et al. Allelotype analysis of hepatocellular carcinoma. Int J Cancer. 1998;75(1):29–33
  56. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120(7):1763–1773
  57. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972–1983
  58. Li W, Tan D, Zhang Z, et al. Activation of Akt-mTOR-p70s6k pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep. 2008;20(4):713–719
  59. Yu K, Toral-Barza L, Discafani C, et al. MTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8(3):249–258
  60. Fujiwara Y, Hoon DS, Yamada T, et al. PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res. 2000;91(3):287–292
  61. Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. J Hepatol. 2007;45(1):42–52
  62. Hui IC, Tung EK, Sze KM, et al. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int. 2009;30(1):65–75
  63. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51(4):725–733
  64. Chen L, Shiah HS, Chen CY, et al. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients(pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2009;27(Suppl):Abstract 4587
  65. Decaens T, Luciani A, Itti E, et al. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. 2009 Gastrointestinal Cancers Symposium. 2009;
  66. Campos LT, Stephenson J, Swan F, et al. Daily dose of perifosine less toxic than weekly and active in patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2007;25(18S):15072
  67. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;25(27):3787–3800
  68. Mínguez B, Tovar V, Chiang D, et al. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25(3):186–194
  69. Kishimoto Y, Morisawa T, Kitano M, et al. Loss of heterozygosity of the mannose 6-phosphate/insulin-like growth factor II receptor and p53 genes in human hepatocellular carcinoma. Hepatol Res. 2001;20(1):68–83
  70. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drugs Discov. 2009;4(1):54–72
  71. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007;13(18 Pt 2):5549s–5555s
  72. Sherr CJ. Growth factor-regulated G1 cyclins. Stem Cells. 1994;12(Suppl 1):47–55discussion 55-7
  73. McDonald ER, El-Deiry WS. Cell cycle control as a basis for cancer drug development (review). Int J Oncol. 2000;16(5):871–886
  74. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350(6317):429–431
  75. Hsu IC, Tokiwa T, Bennett W, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis. 1993;14(5):987–992
  76. Feitelson MA, Zhu M, Duan LX, et al. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 1993;8(5):1109–1117
  77. Fujimoto Y, Hampton LL, Wirth PJ, et al. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res. 1994;54(1):281–285
  78. Boige V, Laurent-Puig P. Genetic alterations associated with hepatocellular carcinoma. Gastroenterol Clin Biol. 1997;21(1):34–44
  79. Nagai H, Pineau P, Tiollais P, et al. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene. 1997;14(24):2927–2933
  80. Rizzolio F, Tuccinardi T, Caligiuri I, et al. CDK inhibitors: from the bench to clinical trials. Curr Drug Targets. 2009;Epub ahead of print
  81. Takeo S, Arai H, Kusano N, et al. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet. 2001;130(2):127–132
  82. Schwartz J, Schwartz M, Lehrer D, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol. 2006;24(Suppl):4144
  83. Malka D, Dromain C, Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol. 2007;25(18S):Abstract 4570
  84. Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102:981–986
  85. Sun W, Haller DG, Mykulowycz K, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol. 2007;25(18S):Abstract 4574
  86. Abrams TJ, Lee LB, Murray LJ, et al. Sun11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471–478
  87. Zhu AX, Sahani DV, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2007;25(18S):Abstract 4637
  88. Faivre S, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2007;25:149s
  89. Hoda D, Catherine C, Strosberg J, et al. Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma (HCC). In: 2008 Gastrointestinal Cancer Symposium Abstract 267. Orlando, FL: American Society of Oncology; 25-27 January 2008;p. 202
  90. Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trail (SAKK77/06 and SASL 23). J Clin Oncol. 2009;27(Suppl):Abstract 4591
  91. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today. 2005;41(12):773–784
  92. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390
  93. Shen Y, Shao Y, Hsu C, et al. A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2009;27(Suppl):Abstract 4589
  94. Petrini I, Lencioni M, Ricasoli M, et al. A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary data. J Clin Oncol. 2009;27(Suppl):Abstract 4592
  95. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992–2998
  96. Malka D, Dromian C, Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol. 2007;25(suppl):Abstract 4570
  97. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(12):1898–1903
  98. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27(6):843–850
  99. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–783
  100. Raoul JL, Finn RS, Kang YK, et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatcellular carcinoma (HCC). J Clin Oncol. 2009;27(Suppl):Abstract 4577
  101. Finn RS, Kang Y, Park J, et al. Phase II, open lable study of brivanib alaninate in patients with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy. In: 2009 Gastroinestinal Cancers Symposium Abstract 200. Orlando, FL: American Society of Oncology; 25-27, January 2009;p. 202

PII: S0147-0272(10)00022-X

doi: 10.1016/j.currproblcancer.2010.03.001

Current Problems in Cancer
Volume 34, Issue 2 , Pages 131-149 , March 2010

Article Tools

* Image Usage & Resolution